Elizabeth Ofili to Double-Blind Method
This is a "connection" page, showing publications Elizabeth Ofili has written about Double-Blind Method.
Connection Strength
0.409
-
Ofili EO, Zappe DH, Purkayastha D, Samuel R, Sowers JR. Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients. Am J Ther. 2013 Jan; 20(1):2-12.
Score: 0.104
-
Ofili EO, Oparil S, Giles T, Pitt B, Purkayastha D, Hilkert R, Samuel R, Sowers JR. Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups. J Am Soc Hypertens. 2011 Jul-Aug; 5(4):249-58.
Score: 0.092
-
Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015 May 19; 131(20):1763-71.
Score: 0.030
-
Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, D?vila-Rom?n VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013 Dec 18; 310(23):2533-43.
Score: 0.028
-
Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013 Mar 27; 309(12):1268-77.
Score: 0.026
-
Giles TD, Oparil S, Ofili EO, Pitt B, Purkayastha D, Hilkert R, Samuel R, Sowers JR. The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. Blood Press Monit. 2011 Apr; 16(2):87-95.
Score: 0.023
-
Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 03; 364(9):797-805.
Score: 0.023
-
Oparil S, Giles T, Ofili EO, Pitt B, Seifu Y, Hilkert R, Samuel R, Sowers JR. Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. J Hypertens. 2011 Jan; 29(1):161-70.
Score: 0.023
-
Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, Adams K, Olukotun AY, Ofili E, Tam SW, Sabolinski ML, Worcel M, Cohn JN. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation. 2007 Apr 03; 115(13):1747-53.
Score: 0.017
-
Weber MA, Bakris GL, Dahl?f B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Weir M, Kjeldsen S, Massie B, Nesbitt S, Ofili E, Jamerson K. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007; 16(1):13-9.
Score: 0.017
-
Okin PM, Wright JT, Nieminen MS, Jern S, Taylor AL, Phillips R, Papademetriou V, Clark LT, Ofili EO, Randall OS, Oikarinen L, Viitasalo M, Toivonen L, Julius S, Dahl?f B, Devereux RB. Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. Am J Hypertens. 2002 Aug; 15(8):663-71.
Score: 0.013
-
Franciosa JA, Taylor AL, Cohn JN, Yancy CW, Ziesche S, Olukotun A, Ofili E, Ferdinand K, Loscalzo J, Worcel M. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail. 2002 Jun; 8(3):128-35.
Score: 0.012